mirtazapine has been researched along with Menopause in 4 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine is an effective treatment for major depression in perimenopausal and postmenopausal women whose depression precedes ERT use and does not respond to ERT or whose depression develops after ERT is initiated." | 6.70 | An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. ( Cohen, LS; Groninger, H; Joffe, H; Nonacs, R; Soares, C; Soares, CN, 2001) |
| "Mirtazapine is an effective treatment for major depression in perimenopausal and postmenopausal women whose depression precedes ERT use and does not respond to ERT or whose depression develops after ERT is initiated." | 2.70 | An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. ( Cohen, LS; Groninger, H; Joffe, H; Nonacs, R; Soares, C; Soares, CN, 2001) |
| "The latter yielded results on VMS, insomnia, circadian rhythm disorders, obstructive sleep apnea (OSA) and restless leg syndrome (RLS)." | 2.61 | Italian Association of Sleep Medicine (AIMS) position statement and guideline on the treatment of menopausal sleep disorders. ( Aricò, I; Bonanni, E; Bonsignore, M; Caretto, M; Caruso, D; Di Perri, MC; Galletta, S; Lecca, RM; Lombardi, C; Maestri, M; Miccoli, M; Palagini, L; Provini, F; Puligheddu, M; Savarese, M; Silvestri, R; Simoncini, T; Spaggiari, MC, 2019) |
| "Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants." | 2.40 | Mirtazapine: other indications. ( Falkai, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silvestri, R | 1 |
| Aricò, I | 1 |
| Bonanni, E | 1 |
| Bonsignore, M | 1 |
| Caretto, M | 1 |
| Caruso, D | 1 |
| Di Perri, MC | 1 |
| Galletta, S | 1 |
| Lecca, RM | 1 |
| Lombardi, C | 1 |
| Maestri, M | 1 |
| Miccoli, M | 1 |
| Palagini, L | 1 |
| Provini, F | 1 |
| Puligheddu, M | 1 |
| Savarese, M | 1 |
| Spaggiari, MC | 1 |
| Simoncini, T | 1 |
| Albertazzi, P | 1 |
| Falkai, P | 1 |
| Joffe, H | 1 |
| Groninger, H | 1 |
| Soares, CN | 1 |
| Nonacs, R | 1 |
| Cohen, LS | 1 |
| Soares, C | 1 |
3 reviews available for mirtazapine and Menopause
| Article | Year |
|---|---|
Italian Association of Sleep Medicine (AIMS) position statement and guideline on the treatment of menopausal sleep disorders.
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Continuous Positive Airway Pressure; Depression | 2019 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapin | 2006 |
Mirtazapine: other indications.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Dis | 1999 |
1 trial available for mirtazapine and Menopause
| Article | Year |
|---|---|
An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy.
Topics: Adult; Antidepressive Agents; Depression; Estradiol; Female; Hormone Replacement Therapy; Humans; Me | 2001 |